Chargement en cours...
Renal outcomes of radioligand therapy: experience of (177)lutetium—prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer
BACKGROUND: Radioligand therapy (RLT) with (177)lutetium (Lu)-labelled prostate-specific membrane antigen (PSMA) ligands has been increasingly used in recent years for therapy of metastatic castrate-resistant prostate cancer (mCRPC). Studies have revealed that (177)Lu-PSMA ligand therapy is well tol...
Enregistré dans:
| Publié dans: | Clin Kidney J |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Oxford University Press
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7769531/ https://ncbi.nlm.nih.gov/pubmed/33391748 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfz101 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|